Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSolly ChedidMBMuhamed Baljević

Discussion

Loading...

Member takes

Overview

Observational study shows increased preference for CAR T-cell therapy in lenalidomide-refractory multiple myeloma, highlighting MRD implications.

Key Points

  • To assess oncologists' treatment preferences and decision-making factors regarding cilta-cel in RRMM.
  • Surveyed U.S. hematologist/oncologists about RRMM treatment practices and CARTITUDE-4 data perceptions.
  • Survey participants excluded if they did not treat hematologic malignancies.
  • Collected and summarized survey responses before and after reviewing trial data.
  • 61% of respondents were dual certified in hematology, with median practice of 15 years.
  • Prior to CARTITUDE-4 data review, 36% referred 1-25% of patients for CAR T; this increased to 88% after.
  • Significantly increased MRD-negativity rates (49%) with cilta-cel noted as a key finding.

Cite This Study

Chedid et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9c7https://doi.org/10.1182/blood-2025-4572
View Full Paper
Ask AI
Bookmark
Share